Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesTreatment of inflammatory bowel disease: A review of medical therapy
World Journal of Gastroenterology, 01/25/08
Kozuch PL et al. - Although 5-ASA agents have been a mainstay in the treatment of both CD and UC, the data for their efficacy in patients with CD, particularly as maintenance therapy, are equivocal. Antibiotics may have a limited role in the treatment of colonic CD. Steroids continue to be the first choice to treat active disease not responsive to other more conservative therapy; non-systemic steroids such as oral and rectal budesonide for ileal and right-sided CD and distal UC respectively are also effective in mild-moderate disease. 6-mercaptopurine (6-MP) and its prodrug azathioprine are steroid-sparing immunomodulators effective in the maintenance of remission of both CD and UC, while methotrexate may be used in both induction and maintenance of CD.
| Previous Article | Next Article |
Today in Stomach/GI...keeping you current
Receive free subspecialty "5-minute updates" via email
Use of Racecadotril as Outpatient Treatment for Acute Gastroenteritis: A Prospective, Randomized, Parallel Stud
The Journal of Pediatrics, 06/30/09
Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, and leucovorin in patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841
Journal of Clinical Oncology, 06/10/09
Prescribing statins to patients with nonalcoholic fatty liver disease: Real cardiovascular benefits outweigh theoretical hepatotoxic risk
Cardiovascular Drug Reviews, 06/26/09
Article Search
Sponsor